Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Earnings data Q4 2022

Earnings data Q1 2023

SOUTH SAN FRANCISCO, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an update on its investigational next-generation hepatitis B virus (HBV) core inhibitors, ABI-H3733 (3733) and ABI-4334 (4334), and reported financial results and recent highlights for the fourth quarter and year ended December 31, 2022.

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Pardes Biosciences

BOSTON--( BUSINESS WIRE )--Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D.

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

AGM Group Holdings Inc - Ordinary Shares - Class A

Ensysce Biosciences

Innate Pharma SA

LianBio

Soleno Therapeutics

Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 6 To Watch With Big News Today

The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)

Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and recent highlights for the second quarter ended June 30, 2022.

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why

Instructure Holdings

Impinj

PI, INST and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2022.

Best Momentum Stocks to Buy for August 4th

Apollo Commercial Real Estate Finance

Chubb

United Rentals

ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.

New Strong Buy Stocks for August 4th

- Discontinues clinical development of vebicorvir, Assembly Bio's first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies

Assembly Biosciences Announces Program Reprioritization and Organizational Update

SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced data from the company's investigational core inhibitor programs ABI-H3733 (3733), ABI-4334 (4334) and vebicorvir (VBR), featured in six poster presentations at the  International Liver Congress™ , the Annual Meeting of the European Association for the Study of the Liver (EASL) taking place virtually and in London on June 22-26, 2022.

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Advent Technologies Holdings

Boxed

Bird Rides

Chimerix

NextNav

Electrameccanica

Some stocks currently trading in penny stock territory have unique advantages that makes it worthwhile to overlook the inherent risk involved in investing in these stocks. The post 7 Penny Stocks That Could Triple in 2022 appeared first on InvestorPlace.

7 Penny Stocks That Could Triple in 2022

SOUTH SAN FRANCISCO, Calif., June 21, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT/4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-α receptor (IFNAR) agonist designed to selectively activate the interferon-α pathway within the liver and offer the convenience of oral dosing.

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that six abstracts have been accepted for presentation at the International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL) taking place virtually and in London on June 22-26, 2022. During the meeting, data from Assembly Bio's investigational core inhibitor programs, vebicorvir (VBR), ABI-H3733 (3733) and ABI-4334 (4334), will be featured in six poster presentations.

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor ABI-H3733 (3733).

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced a grant of stock options to one new employee to purchase 16,000 shares of Assembly Bio common stock with an exercise price of $1.87 per share, the closing price of Assembly Bio's common stock on June 1, 2022. The stock options were granted as a material inducement to a new employee to accept Assembly Bio's offer of employment.

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the first quarter ended March 31, 2022.

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2021.

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, AO, MD, chief executive officer and president, will participate in a virtual fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 p.m. ET.

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced grants of stock options to two new employees to purchase an aggregate of 7,000 shares of the Company's common stock with an exercise price of $2.45 per share, the closing price of Assembly Bio's common stock on January 3, 2022. The stock options were granted as material inducements to the new employees to accept the Company's offers of employment.

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, AO, MD, chief executive officer and president, will present during the HC Wainwright Virtual BIOCONNECT Conference, January 10-13, 2022.

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

Assembly Biosciences (ASMB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB)

Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation

News for Assembly Biosciences Stock (ASMB)